https://www.marketscreener.com/quote/stock/IMMUNIC-INC-57237730/news/Immunic-Inc-Reports-Positive-Top-line-Data-from-Phase-2-EMPhASIS-Trial-of-IMU-838-in-Patients-wi-31042227/?utm_source=telegram&utm_medium=social&utm_campaign=share